Key Developments: Carl Zeiss Meditec AG (CZMWY.PK)
31.85USD
1 Apr 2013
$0.56 (+1.79%)
$31.29
$31.85
$31.85
$31.85
200
150
$33.95
$22.95
Latest Key Developments (Source: Significant Developments)
Carl Zeiss Meditec AG Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call
Carl Zeiss Meditec AG announced that for fiscal 2013, it expects revenues of between EUR880 million and EUR910 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of EUR 905 million for fiscal 2013. Full Article
Carl Zeiss Meditec AG to Propose FY 2011/2012 Dividend
Carl Zeiss Meditec AG announced that on November 29, 2012 at its meeting to adopt the financial statements, the Supervisory Board of the Company agreed to the Management Board's recommendation to propose to the Annual General Meeting on March 5, 2013 the payment of a regular dividend for the fiscal year 2011/2012 of EUR 0.40 per no-par value share (previous fiscal year: EUR 0.30). This would increase the total dividend by 33.3% compared with the previous fiscal year, to EUR 32.5 million. The dividend ratio as a share of consolidated net income after non-controlling interests would be 45.3%. Full Article
Carl Zeiss Meditec AG Confirms FY 2011/2012 Revenue Guidance; Confirms EBIT Margin Outlook till Year 2015
Carl Zeiss Meditec AG announced that it has confirmed its revenue forecast for the fiscal year 2011/2012. The Company anticipates revenue of between EUR 830 million and EUR 860 million for the fiscal year 2011/2012, which would correspond to a growth corridor of between 9% and 13%. Furthermore, the Company announced that it is adhering to its previously forecast target of an EBIT margin of 15% by the year 2015. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2012 revenue of EUR 860.75 million. Full Article
Carl Zeiss Meditec AG Comments on INFRARED 800 and FLOWR 800 Fluorescence Modules Testing Results
Carl Zeiss Meditec AG announced that the INFRARED 800 and FLOWR 800 fluorescence modules enable neurosurgeons to interpret the speed and direction of the blood flow precisely and quickly during surgery. This technology is also available for plastic & reconstructive surgery in the assessment of viable tissue useful in graft surgery. This technological advancement enables surgeons to evaluate tissue grafts perfusion before transplantation. Vascular occlusions become visible within a few seconds and can be immediately treated intraoperatively. Initial study results confirm the benefits for plastic and reconstructive surgery as well as the benefits of intraoperative fluorescence technology for plastic surgery, in particular for flap graft. Full Article
Carl Zeiss Meditec AG Issues FY 2011/2012 Guidance In Line with Analysts' Estimates; Confirms EBIT Margin Outlook till FY 2015
Carl Zeiss Meditec AG announced that for the fiscal year 2011/2012 the Company targets revenue of between EUR 830 million and EUR 860 million. This corresponds to an increase of approximately 9.4% to 13.3% over the fiscal year 2010/2011. Furthermore, the Company announced that it still expects to achieve EBIT margin of 15% till the fiscal year 2015. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2012 revenue of EUR 846.57 million. Full Article
Carl Zeiss Meditec AG Issues H1 FY 2011/2012 Guidance
Carl Zeiss Meditec AG announced that it will report revenue of approximately EUR 432 million for the first half of the current financial year 2011/2012. This corresponds to an increase of approximately 15% over the equivalent period last year. Earnings before interest and tax are also expected to increase compared with the previous year. Full Article
Carl Zeiss Meditec AG Comments On FY 2015 Profit Guidance-Conference Call
Carl Zeiss Meditec AG announced that it expects to increase profitability level to 15% in year fiscal 2015. Full Article
Carl Zeiss Meditec AG Invests in Sales Expansion in Spain
Carl Zeiss Meditec AG announced that it intends to acquire the intraocular lens (IOLs) and ophthalmic viscoelastic devices (OVDs) business of IMEX, Spain, to strengthen its sales, service and support network in Spain. This is the objective of an asset purchase agreement signed by both parties this evening in Vienna, Austria. Until now, IMEX has been the exclusive partner of Carl Zeiss Meditec for its IOL & OVD business on the Iberian Peninsula. The purchase price is EUR 9 million plus a performance driven component of additionally EUR 8 million in case of complete achievement of certain defined targets over the period of 2.5 years. Full Article
UPDATE 4-Dell says Blackstone, Icahn offers may be superior
* Dell says Michael Dell willing to work with third parties
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
